COVID-19: counter-intuitive data on smoking prevalence and therapeutic implications for nicotine
- PMID: 32430652
- PMCID: PMC7236870
- DOI: 10.1007/s11739-020-02361-9
COVID-19: counter-intuitive data on smoking prevalence and therapeutic implications for nicotine
Conflict of interest statement
RP is full-time employee at the University of Catania, Italy. In relation to the topic of communicable disease, RP has received research funding from Alfa-Wassermann, manufacturer of broad spectrum antibiotics. RP is also founder of the Center of Excellence for the acceleration of Harm Reduction at the University of Catania (CoEHAR), which has received a grant from Foundation for a Smoke Free World to develop and carry out 8 research projects and scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti-Smoking League). GC has no conflict of interest.
Comment on
-
Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?Intern Emerg Med. 2020 Aug;15(5):845-852. doi: 10.1007/s11739-020-02355-7. Epub 2020 May 9. Intern Emerg Med. 2020. PMID: 32385628 Free PMC article.
References
-
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
